The US Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with Perjeta (pertuzumab) as the first new first-line treatment in ten years for HER2-positive metastatic breast cancer.
The US Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with Perjeta (pertuzumab) as the first new first-line treatment in ten years for HER2-positive metastatic breast cancer.